Inhalable curcumin: Offering the potential for translation to imaging and treatment of Alzheimer's disease

Journal of Alzheimer's Disease

Volumn 44, Issue 1, 2015, Pages 283-295

  McClure, Richard ^a,b   Yanagisawa, Daijiro ^c   Stec, Donald ^d   Abdollahian, Dave ^a,b   Koktysh, Dmitry ^d,e   Xhillari, Dritan ^f   Jaeger, Rudolph ^f   Stanwood, Gregg ^b,g   Chekmenev, Eduard ^a,b,e,g   Tooyama, Ikuo ^c   Gore, John C ^a,b,d,e,g   Pham, Wellington ^a,b,e,g  

^a VANDERBILT UNIVERSITY   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

^d VANDERBILT UNIVERSITY   (United States)

^e VANDERBILT UNIVERSITY   (United States)

^f CH Technologies Inc   (United States)

^g VANDERBILT INGRAM CANCER CENTER   (United States)

Author keywords

Aerosol; Alzheimer's disease; Amyloid imaging; Amyloid plaques; Atomization; Clinical translation; Curcumin; Inhalation exposure

Indexed keywords

CURCUMIN; FLUORINE; FMEC1; PERFLUORO COMPOUND; UNCLASSIFIED DRUG; AMYLOID PRECURSOR PROTEIN; NONSTEROID ANTIINFLAMMATORY AGENT; PRESENILIN 1; PSEN1 PROTEIN, HUMAN;

5XFAD MOUSE; AEROSOL; ALZHEIMER DISEASE; AMYLOID PLAQUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; BRAIN PERFUSION; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG EXPOSURE; EX VIVO STUDY; FLUORESCENCE; FLUORESCENCE MICROSCOPY; HIPPOCAMPUS; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; MOUSE; NEBULIZATION; NEBULIZER; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; ANIMAL; BRAIN; C57BL MOUSE; CHEMISTRY; DIAGNOSTIC IMAGING; DISEASE MODEL; DRUG EFFECTS; GENETICS; HUMAN; INHALATIONAL DRUG ADMINISTRATION; METABOLISM; MUTATION; PATHOLOGY; TISSUE DISTRIBUTION; TRANSGENIC MOUSE;

ADMINISTRATION, INHALATION; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BRAIN; CURCUMIN; DIAGNOSTIC IMAGING; DISEASE MODELS, ANIMAL; HUMANS; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MUTATION; PLAQUE, AMYLOID; PRESENILIN-1; TISSUE DISTRIBUTION;

EID: 84920829360     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-140798     Document Type: Article

References (49)

1. Abbott A (2008) Neuroscience: The plaque plan. Nature 456, 161-164.
2. ThiesW, Bleiler L (2013) 2013 Alzheimer's disease facts and figures. Alzheimers Dement 9, 208-245.
3. Pardridge WM (2002) Drug and gene delivery to the brain: The vascular route. Neuron 36, 555-558.
4. PhamW, Kircher MF, Weissleder R, Tung CH (2004) Enhancing membrane permeability by fatty acylation of oligoarginine peptides. Chembiochem 5, 1148-1151.
5. Pham W, Zhao BQ, Lo EH, Medarova Z, Rosen B, Moore A (2005) Crossing the blood-brain barrier: A potential application of myristoylated polyarginine for in vivo neuroimaging. Neuroimage 28, 287-292.
6. Wang P, Su C, Li R, Wang H, Ren Y, Sun H, Yang J, Sun J, Shi J, Tian J, Jiang S (2014) Mechanisms and effects of curcumin on spatial learning and memory improvement in APPswe/PS1dE9 mice. J Neurosci Res 92, 218-231.
7. Marchiani A, Rozzo C, Fadda A, Delogu G, Ruzza P (2014) Curcumin and curcumin-like molecules: From spice to drugs. Curr Med Chem 21, 204-222.
8. Ray B, Bisht S, Maitra A, Lahiri DK (2011) Neuroprotective and neurorescue effects of a novel polymeric nanoparticle formulation of curcumin (NanoCurc) in the neuronal cell culture and animal model: Implications for Alzheimer's disease. J Alzheimers Dis 23, 61-77.
9. Rahman I, Biswas SK, Kirkham PA (2006) Regulation of inflammation and redox signaling by dietary polyphenols. Biochem Pharmacol 72, 1439-1452.
10. Tirkey N, Kaur G, Vij G, Chopra K (2005) Curcumin, a diferuloylmethane, attenuates cyclosporine-induced renal dysfunction and oxidative stress in rat kidneys. BMC Pharmacol 5, 15.
11. Aggarwal BB, Sundaram C, Malani N, Ichikawa H (2007) Curcumin: The Indian solid gold. Adv Exp Med Biol 595, 1-75.
12. Corona-Rivera A, Urbina-Cano P, Bobadilla-Morales L, Vargas-Lares Jde J, Ramirez-Herrera MA, Mendoza-Magaua ML, Troyo-Sanroman R, Diaz-Esquivel P, Corona-Rivera JR (2007) Protective in vivo effect of curcumin on copper genotoxicity evaluated by comet and micronucleus assays. J Appl Genet 48, 389-396.
13. Garcia-Alloza M, Borrelli LA, Rozkalne A, Hyman BT, Bacskai BJ (2007) Curcumin labels amyloid pathology in vivo, disrupts existing plaques, and partially restores distorted neurites in an Alzheimer mouse model. J Neurochem 102, 1095-1104.
14. Yang F, Lim GP, Begum AN, Ubeda OJ, Simmons MR, Ambegaokar SS, Chen PP, Kayed R, Glabe CG, Frautschy SA, ColeGM(2005) Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J Biol Chem 280, 5892-5901.
15. Ryu EK, Choe YS, Lee KH, Choi Y, Kim BT(2006) Curcumin and dehydrozingerone derivatives: Synthesis, radiolabeling, and evaluation for beta-amyloid plaque imaging. J Med Chem 49, 6111-6119.
16. Yanagisawa D, Amatsubo T, Morikawa S, Taguchi H, Urushitani M, Shirai N, Hirao K, Shiino A, Inubushi T, Tooyama I (2011) In vivo detection of amyloid beta deposition using (1)(9)F magnetic resonance imaging with a (1)(9)F-containing curcumin derivative in a mouse model of Alzheimer's disease. Neuroscience 184, 120-127.
17. Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB (2007) Bioavailability of curcumin: Problems and promises. Mol Pharm 4, 807-818.
18. Prasad S, Tyagi AK, Aggarwal BB (2014) Recent developments in delivery, bioavailability, absorption and metabolism of curcumin: The golden pigment from golden spice. Cancer Res Treat 46, 2-18.
19. Yanagisawa D, Taguchi H, Ibrahim NF, Morikawa S, Shiino A, Inubushi T, Hirao K, Shirai N, Sogabe T, Tooyama I (2014) Preferred features of a fluorine-19 MRI probe for amyloid detection in the brain. J Alzheimers Dis 39, 617-631.
20. Oakley H, Cole SL, Logan S, Maus E, Shao P, Craft J, Guillozet-Bongaarts A, Ohno M, Disterhoft J, Van Eldik L, Berry R, Vassar R (2006) Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: Potential factors in amyloid plaque formation. J Neurosci 26, 10129-10140.
21. Phipps PR, Gonda I (1990) Droplets produced by medical nebulizers. Some factors affecting their size and solute concentration. Chest 97, 1327-1332.
22. Kumagai H, Pham W, Kataoka M, Hiwatari K, McBride J, Wilson KJ, Tachikawa H, Kimura R, Nakamura K, Liu EH, Gore JC, Sakuma S (2013) Multifunctional nanobeacon for imaging Thomsen-Friedenreich antigen-associated colorectal cancer. Int J Cancer 132, 2107-2117.
23. Bolte S, Cordelieres FP (2006) A guided tour into subcellular colocalization analysis in light microscopy. J Microsc 224, 213-232.
24. McClure RA, Chumbley CW, Reyzer ML, Wilson K, Caprioli RM, Gore JC, PhamW(2013) Identification of promethazine as an amyloid-binding molecule using a fluorescence highthroughput assay and MALDI imaging mass spectrometry. Neuroimage Clin 2, 620-629.
25. Donaldson K, Stone V, Tran CL, KreylingW, Borm PJ (2004) Nanotoxicology. Occup Environ Med 61, 727-728.
26. Oberdorster G, Sharp Z, Atudorei V, Elder A, Gelein R, Kreyling W, Cox C (2004) Translocation of inhaled ultrafine particles to the brain. Inhal Toxicol 16, 437-445.
27. Mistry A, Glud SZ, Kjems J, Randel J, Howard KA, Stolnik S, Illum L (2009) Effect of physicochemical properties on intranasal nanoparticle transit into murine olfactory epithelium. J Drug Target 17, 543-552.
28. Rothen-Rutishauser BM, Schurch S, Haenni B, Kapp N, Gehr P (2006) Interaction of fine particles and nanoparticles with red blood cells visualized with advanced microscopic techniques. Environ Sci Technol 40, 4353-4359.
29. Nemmar A, Vanbilloen H, Hoylaerts MF, Hoet PH, Verbruggen A, Nemery B (2001) Passage of intratracheally instilled ultrafine particles from the lung into the systemic circulation in hamster. Am J Respir Crit Care Med 164, 1665-1668.
30. Geiser M, Rothen-Rutishauser B, Kapp N, Schurch S, Kreyling W, Schulz H, Semmler M, Im Hof V, Heyder J, Gehr P (2005) Ultrafine particles cross cellular membranes by nonphagocytic mechanisms in lungs and in cultured cells. Environ Health Perspect 113, 1555-1560.
31. Chiu SS, Lui E, Majeed M, Vishwanatha JK, Ranjan AP, Maitra A, Pramanik D, Smith JA, Helson L (2011) Differential distribution of intravenous curcumin formulations in the rat brain. Anticancer Res 31, 907-911.
32. Garbuzenko OB, Saad M, Pozharov VP, Reuhl KR, Mainelis G, Minko T (2010) Inhibition of lung tumor growth by complex pulmonary delivery of drugs with oligonucleotides as suppressors of cellular resistance. Proc Natl Acad Sci U S A 107, 10737-10742.
33. goindi S, Mann K, Aggarwal N (2011) Gastro-retention floating beads of curcumin beta-cyclodextrin complex to treat stomach tumors. Alternative Med Studies 1, 49-53.
34. Brondino N, Re S, Boldrini A, Cuccomarino A, Lanati N, Barale F, Politi P (2014) Curcumin as a therapeutic agent in dementia: A mini systematic review of human studies. ScientificWorldJournal 2014, 174282.
35. Baum L, Lam CW, Cheung SK, Kwok T, Lui V, Tsoh J, Lam L, Leung V, Hui E, Ng C, Woo J, Chiu HF, Goggins WB, Zee BC, Cheng KF, FongCY, Wong A, MokH, ChowMS, Ho PC, Ip SP, Ho CS, Yu XW, Lai CY, Chan MH, Szeto S, Chan IH, Mok V (2008) Six-month randomized, placebo-controlled, double-blind, pilot clinical trial of curcumin in patients with Alzheimer disease. J Clin Psychopharmacol 28, 110-113.
36. Ringman JM, Frautschy SA, Teng E, Begum AN, Bardens J, Beigi M, Gylys KH, Badmaev V, Heath DD, Apostolova LG, PorterV, Vanek Z, Marshall GA, Hellemann G, Sugar C, Masterman DL, Montine TJ, Cummings JL, Cole GM (2012) Oral curcumin for Alzheimer's disease: Tolerability and efficacy in a 24-week randomized, double blind, placebo-controlled study. Alzheimers Res Ther 4, 43.
37. Sasaki H, Sunagawa Y, Takahashi K, Imaizumi A, Fukuda H, Hashimoto T, Wada H, Katanasaka Y, Kakeya H, Fujita M, Hasegawa K, Morimoto T (2011) Innovative preparation of curcumin for improved oral bioavailability. Biol Pharm Bull 34, 660-665.
38. Cheng KK, Yeung CF, Ho SW, Chow SF, Chow AH, Baum L (2013) Highly stabilized curcumin nanoparticles tested in an in vitro blood-brain barrier model and in Alzheimer's disease Tg2576 mice. AAPS J 15, 324-336.
39. Anand P, Nair HB, Sung B, Kunnumakkara AB, Yadav VR, Tekmal RR, Aggarwal BB (2010) Design of curcumin-loaded PLGA nanoparticles formulation with enhanced cellular uptake, and increased bioactivity in vitro and superior bioavailability in vivo. Biochem Pharmacol 79, 330-338.
40. Khalil NM, do Nascimento TC, Casa DM, Dalmolin LF, de MattosAC, Hoss I, Romano MA, MainardesRM(2013) Pharmacokinetics of curcumin-loaded PLGA and PLGA-PEG blend nanoparticles after oral administration in rats. Colloids Surf B Biointerfaces 101, 353-360.
41. Gandapu U, Chaitanya RK, Kishore G, Reddy RC, Kondapi AK (2011) Curcumin-loaded apotransferrin nanoparticles provide efficient cellular uptake and effectively inhibit HIV-1 replication in vitro. PLoS One 6, e23388.
42. Goel A, Kunnumakkara AB, Aggarwal BB (2008) Curcumin as "Curecumin": From kitchen to clinic. Biochem Pharmacol 75, 787-809.
43. PanMH, Huang TM, Lin JK (1999) Biotransformation of curcumin through reduction and glucuronidation in mice. Drug Metab Dispos 27, 486-494.
44. Ireson CR, Jones DJ, Orr S, Coughtrie MW, Boocock DJ, Williams ML, Farmer PB, Steward WP, Gescher AJ (2002) Metabolism of the cancer chemopreventive agent curcumin in human and rat intestine. Cancer Epidemiol Biomarkers Prev 11, 105-111.
45. Subhashini, Chauhan PS, Kumari S, Kumar JP, Chawla R, Dash D, Singh M, Singh R (2013) Intranasal curcumin and its evaluation in murine model of asthma. Int Immunopharmacol 17, 733-743.
46. Hoppe JB, Coradini K, Frozza RL, Oliveira CM, Meneghetti AB, Bernardi A, Pires ES, Beck RC, Salbego CG (2013) Free and nanoencapsulated curcumin suppress beta-amyloidinduced cognitive impairments in rats: Involvement of BDNF and Akt/GSK-3beta signaling pathway. Neurobiol LearnMem 106, 134-144.
47. Hoppe JB, Frozza RL, Pires EN, Meneghetti AB, Salbego C (2013) The curry spice curcumin attenuates beta-amyloidinduced toxicity through beta-catenin and PI3K signaling in rat organotypic hippocampal slice culture. Neurol Res 35, 857-866.
48. Hoppe JB, Haag M, Whalley BJ, Salbego CG, Cimarosti H (2013) Curcumin protects organotypic hippocampal slice cultures from Abeta1-42-induced synaptic toxicity. Toxicol In Vitro 27, 2325-2330.
49. Kumaraswamy P, Sethuraman S, Krishnan UM (2013) Mechanistic insights of curcumin interactions with the corerecognition motif of beta-amyloid peptide. J AgricFood Chem 61, 3278-3285.